Table 3.
rs (95% CI) | Tapping Hits Non-dominant or More Affected Hand |
Tremor Amplitude (mM) Non-Dominant Hand or More Affected Hand |
MDS-UPDRS3 Total Score |
MDS-UPDRS3 Rigidity Subscore |
---|---|---|---|---|
Age (years) | −0.10 (−0.42, 0.24) | 0.09 (−0.25, 0.41) | 0.34 (0.01, 0.61) | 0.19 (−0.16, 0.49) |
Age at diagnosis (years) | −0.11 (−0.43, 0.23) | 0.17 (−0.18, 0.47) | 0.26 (−0.08, 0.54) | 0.07 (−0.27, 0.39) |
R2* (1/s) SN | 0.11 (−0.23, 0.43) | 0.02 (−0.32, 0.35) | 0.39 (0.07, 0.64) | 0.33 (−0.01, 0.59) |
R2* (1/s) GP | −0.04 (−0.37, 0.29) | 0.00 (−0.34, 0.33) | 0.32 (−0.01, 0.59) | 0.32 (−0.01, 0.59) |
Striatum | ||||
GABA | 0.31 (−0.14, 0.65) | 0.13 (−0.32, 0.53) | 0.37 (−0.08, 0.69) | 0.30 (−0.15, 0.65) |
Glx | −0.30 (−0.66, 0.16) | 0.03 (−0.42, 0.47) | −0.14 (−0.55, 0.32) | −0.23 (−0.61, 0.24) |
Myo-inositol | 0.49 (0.06, 0.77) | −0.34 (−0.68, 0.12) | 0.30 (−0.16., 0.66) | 0.03 (−0.42, 0.47) |
Total creatine | 0.06 (−0.39, 0.49) | −0.29 (−0.65, 0.18) | 0.14 (−0.32, 0.55) | 0.01 (−0.44, 0.45) |
Thalamus | ||||
GABA | −0.11 (−0.55, 0.38) | −0.20 (−0.61, 0.30) | −0.01 (−0.47, 0.46) | −0.15 (−0.58, 0.34) |
Glx | 0.16 (−0.30, 0.56) | −0.03 (−0.47, 0.42) | 0.15 (−0.31, 0.56) | 0.11 (−0.35, 0.52) |
Myo-inositol | −0.10 (−0.52, 0.36) | 0.03 (−0.42, 0.47) | −0.19 (−0.58, 0.28) | −0.30 (−0.65, 0.17) |
Total creatine | 0.26 (−0.20, 0.63) | −0.01 (−0.45, 0.43) | 0.01 (−0.44, 0.45) | −0.12 (−0.54, 0.34) |
Abbreviations: MDS-UPDRS3: Movement Disorder Society-Sponsored Revision of the Unified Parkinson Disease Rating Scale part III, R: relaxation rate, SN: substantia nigra, GP: globus pallidus, GABA: γ-aminobutyric acid, Glx: glutamate and glutamine, rs: Spearman correlation coefficients (for neurometabolites partial correlation coefficients adjusted for CSF content in the voxels using data from the hemisphere contralateral to the non-dominant hand for tapping hits and tremor amplitude), CI: confidence interval (significant effects marked in bold and marginal effects marked in italic).